Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity

Gene Therapy

Volumn 5, Issue 2, 1998, Pages 223-232

  Chong, H ^a   Todryk, S ^b   Hutchinson, G ^c   Hart, I R ^c   Vile, R G ^b  

^a St Thomas' Hospitals

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Colorectal tumour; Costimulation; Gene therapy; GM CSF; IL 12; Melanoma

Indexed keywords

B7 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOSTIMULATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNITY;

ANIMALIA; MURINAE;

EID: 0031885545     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300584     Document Type: Article

References (68)

1. Colombo MF, Forni G. Immunotherapy, I: Cytokine gene transfer strategies. Cancer Metes Rev 1996; 15: 317-328.
2. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994; 5: 153-164.
3. Pardoll DM. Cancer vaccines. Immunol Today 1993; 14: 310-316.
4. Huang AYC et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-965.
5. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Ann Rev Immunol 1993; 11: 191-212.
6. Freeman GJ et al. Structure, expression and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med 1991; 174: 625-631.
7. Freeman GJ et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993; 262: 909-911.
8. Azuma M et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993; 366: 76-79.
9. Gimmi CD et al. B cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA 1991; 88: 6575-6579.
10. Boon T et al. Tumor antigens recognised by lymphocytes. Ann Rev Immunol 1994; 12: 337-365.
11. Vile RG, Chong H, Dorudi S. The immunosurveillance of cancer: specific and non-specific mechanisms. In: Dalgleish AC, Browning MJ (eds) Tumor Immunology. Cambridge University Press: New York, 1996, pp 7-38.
12. Chen L et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-1102.
13. - T cells by B7-transfected melanoma cells. Science 1993; 259: 368-370.
14. Cavallo F et al. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol 1995; 25: 1154-1162.
15. Dunussi-Joannopoulos K et al. Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 1996; 87: 2938-2946.
16. Martin-Fontecha A et al. Heterogenous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Eur J Immunol 1996; 26: 1851-1859.
17. Gajewski TF et al. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor. J Immunol 1996; 156: 2909-2917.
18. Ramarathinam L et al. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment and effector function of antitumor T cells. J Exp Med 1994; 179: 1205-1214.
19. Chen L et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994; 179: 523-532.
20. Chong H et al. Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity. Hum Gene Ther 1996; 7: 1771-1779.
21. Huang A et al. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996; 183: 769-776.
22. Cayeux B et al. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. J Immunol 1997; 158: 2834-2841.
23. Wu T-Z et al. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995; 182: 1415-1421.
24. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann Rev Immunol 1995; 13: 251-276.
25. Kubin M, Kamoun M, Trinchieri G. lnterleukin-12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 1994; 180: 211-222.
26. Murphy E et al. B7 and interleukin-12 co-operate for proliferation and interferon-γ production by mouse T helper clones that are unresponsive to B7 costimulation. J Exp Med 1994; 180: 223-231.
27. Voest EE et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581-586.
28. Schoenhaut DS et al. Cloning and expression of murine IL-12. J Immunol 1992; 148: 3433-3440.
29. Mattner F et al. The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer. Eur J Immunol 1993; 23: 2202-2208.
30. Kato K et al. Local production of the p40 subunit of interleukin-12 suppresses T-helper 1-mediated immune responses and prevents allogeneic myoblast rejection. Proc Natl Acad Sci USA 1996; 93: 9085-9089.
31. Chen L et al. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol 1997; 159: 351-359.
32. Brunda M et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 1993; 178: 1223-1230.
33. Tahara H et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995; 154: 6466-6474.
34. Cavallo F et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin-12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 1997; 89: 1049-1058.
35. Bramson JL et al. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 1996; 7: 1995-2002.
36. Caruso M et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 1996; 93: 11302-11306.
37. Rakhmilevich AL et al. Gene gun-mediated skin transfection with interleukin-12 gene results in regression of established primarry and metastatic murine tumors. Proc Natl Acad Sci USA 1996; 93: 6291-6296.
38. Caux C et al. GM-CSF and TNF-α co-operate in the generation of dendritic Langerhans cells. Nature 1992; 360: 258-261.
39. Larsen CP et al. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol 1994; 152: 5208-5219.
40. Levitsky HI et al. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 1994, 179: 1215-1224.
41. Levitsky HI et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996; 156: 3858-3865.
42. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
43. Castleden SA et al. A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model. Hum Gene Ther (in press).
44. Allione A et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (ID-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor and γ-interferon gene or admixed with conventional adjuvants. Cancer Res 1994; 54: 6022-6026.
45. Cayeux S et al. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur J Immunol 1995; 25: 2325-2331.
46. Santodonato L et al. Cure of mice with established metastatic Friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon-α1 and herpes simplex thymidine kinase followed by ganciclovir. Hum Gene Ther 1996; 7: 1-10.
47. Boussiotis VA et al. The role of B7-1/B7-2:CD28/CTLA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol Rev 1996; 153: 5-19.
48. Freeman GJ et al. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4 Immunity 1995; 2: 523-532.
49. Lenschow DJ et al. Differential effects of anti-B7-l and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995, 181: 1145-1155.
50. Kuchroo VK et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1 /Th2 developmental pathways application to autoimmune disease therapy. Cell 1995; 80: 707-718.
51. Lanier LL et al. CD80(B7) and CD86(B70) provide similar costimulatory signals for T cell proliferation, cytokine production and generation of CTL J Immnnol 1995; 154: 97-105.
52. + T cells and induce similar patterns of cytokine secretion in vitro. Int Immunol 1995; 7: 891-904.
53. Schweitzer AN et al. Role of costimulators in T cell differentiation. J Immunol 1997; 158: 2715-2722.
54. Yang G et al. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 1995; 154: 2794-2800.
55. Matulonis U et al. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. J Immunol 1996; 156: 1126-1131.
56. Cayeux S et al. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency. Eur J Immunol 1997; 27: 1657-1662
57. Zitvogel L et al. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 1996; 26: 1335-1341.
58. Coughlin CM et al. B7-1 and interleukin-12 synergistically induce effective antitumor immunity. Cancer Res 1995, 55: 4980-4987.
59. Chen PW et al. Tumor cells transfected with B7-1 and interleukin-12 cDNA induce protective immunity. Ann NY Acad Sci 1996; 795: 325-327.
60. Parney IF et al. Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model. Hum Gene Ther 1997; 8: 1073-1085.
61. Salvadori S et al. B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro. Hum Gene Ther 1995; 6: 1299-1306.
62. Cayeux S et al Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared with single gene transfectants and a classical adjuvant. Hum Gene Ther 1996; 7: 525-529.
63. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: New York, 1989.
64. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990; 18: 3587-3596.
65. Vile RG et al. Systemic gene therapy of murine melanoma using tissue-specific expression of the HSVtk gene involves an immune component. Cancer Res 1994; 54: 6228-6234.
66. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988; 167: 400-406.
67. Lane P et al. Expression and functional properties of mouse B7/BB1 using a fusion protein between mouse CTLA4 and human gamma 1. Immunology 1993; 80: 56-61.
68. Altman DG. Practical Statistics for Medical Research. Chapman & Hall: London, 1991.